|
|
|
Insider
Information: |
Leung Sandra |
Relationship: |
Director |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
348,885 |
|
Indirect Shares
|
100,721 |
|
|
Direct
Value |
$14,326,157 |
|
|
Indirect Value
|
$4,153,734 |
|
|
Total
Shares |
449,606 |
|
|
Total
Value |
$18,479,891 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
2
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
Percentage
Gain/Loss : |
0.0%
|
7.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Bristol-Myers Squibb Co |
BMY |
EVP, General Counsel |
2024-03-10 |
347,385 |
2024-03-10 |
100,721 |
Premium* |
|
Mead Johnson Nutrition Co |
MJN |
Director |
2009-02-17 |
1,500 |
2009-02-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
133 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
65,424 |
451,862 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2017-12-04 |
4 |
OE |
$22.14 |
$3,466,725 |
D/D |
156,582 |
584,373 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2017-12-04 |
4 |
S |
$63.37 |
$9,922,601 |
D/D |
(156,582) |
427,791 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2018-03-10 |
4 |
D |
$67.92 |
$2,352,885 |
D/D |
(34,642) |
464,585 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2018-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,896 |
488,677 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2018-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,540 |
441,948 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2019-02-28 |
4 |
OE |
$17.51 |
$2,974,826 |
D/D |
169,893 |
634,478 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2019-02-28 |
4 |
D |
$51.86 |
$5,697,028 |
D/D |
(109,854) |
524,624 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2019-03-10 |
4 |
D |
$51.39 |
$1,038,335 |
D/D |
(20,205) |
546,080 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,170 |
558,854 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,509) |
534,266 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(298) |
555,623 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,598 |
588,175 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,096 |
591,284 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2020-03-10 |
4 |
D |
$57.93 |
$1,640,114 |
D/D |
(28,312) |
574,164 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2020-08-13 |
4 |
S |
$63.24 |
$8,943,401 |
D/D |
(141,420) |
432,744 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2021-03-10 |
4 |
D |
$60.93 |
$1,901,016 |
D/D |
(31,200) |
369,357 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,554 |
387,579 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,373 |
383,564 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2021-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(413) |
351,776 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2021-07-30 |
4 |
S |
$68.04 |
$1,999,696 |
D/D |
(29,390) |
339,967 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,273 |
388,747 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
18,288 |
403,642 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2022-03-10 |
4 |
D |
$68.42 |
$3,072,126 |
D/D |
(44,901) |
373,627 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, General Counsel |
|
2022-06-06 |
4 |
S |
$74.89 |
$4,867,850 |
D/D |
(65,000) |
308,627 |
0 |
% |
|
133 Records found
|
|
Page 5 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|